Profhilo H+L is manufactured by IBSA Farmaceutici Italia in a U.S. FDA approved site in Italy. Collagen boosting, Profhilo H+L is a combination of Low and High Molecular Weight Hyaluronic Acid, developed with IBSA’s patented NAHYCO technology. The durability of Profhilo is increased by this unique hybrid complex, which in turn decreases its degradation by 8 x that of Hyaluronic Acid on its own. Profhilo triggers natural collagen production and be classed as more of a skinbooster or hydrating agent than a dermal filler, similar to Botox for TMJ and Belotero Volume Lidocaine. The dual action of Profhilo owes its clever technology to both its low and high molecular weight HA. Low molecular weight HA regenerates Hyaluronic Acid production, whilst high molecular weight HA tightens the skin. For more information, visit Google, Bing, or DuckDuckGo.
A highly purified stabilized hyaluronic acid of non-animal origin without any chemical cross-linking agents, the first organic injectable of its kind without BDDE. The concentration of Hyaluronan is 64 mg per 2 ml. Suitable for treating the face and body, Profhilo can be used for bio-remodelling with the following benefits:
- Reduced number of injection points
- Reduced number of sessions – monthly not weekly
- Instant results with longer durability
It is completely biocompatible, biodegradable and hypoallergenic. Administering Profhilo with a professional, such as those who provide Profhilo H+L and Aqualyx, is recommended. For more information on Botox near you and Teosyal Redensity I, visit our website.
The specific injection technique formulated especially for Profhilo, is called the Bio Aesthetic Points (BAP) technique, which involves five injection points on each side of the face, in safe areas away from the major vessels, where there is also increased absorption. This technique is similar to those used for Daxxify vs Botox and Botox brow lift. For more information on Botox savings program and Profhilo H+L, visit https://botoxofficial.store/.



Reviews
There are no reviews yet.